NCT01859637 - Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

September 30, 2015

Conditions

Severe Chronic Neutropenia

Interventions

BIOLOGICAL

Filgrastim

Zarzio®/Filgrastim HEXAL® solution for injection was provided in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU). Dosage and duration for each patient is as per the recommendations in the SmPC.

Trial Locations (2)

Unknown

Medizinischen Hochschule (MHH) Hannover, Hanover

Karolinska Institut, Stockholm